ARGX.BR Argenx Se
Performance
-0.72% Past Week
Market Cap
18.47B
Day’s Range
52W Range
Volume (3M)
49.36K
Price-Earnings Ratio
-26.97
Revenue
398.34M
Argenx Se Latest News
About Argenx Se
Founded in 2008, Argenx SE is a Dutch pharmaceutical company specialising in the research and development of cures for cancer and autoimmune diseases. The company focuses on medicinal solutions in areas where little progress has been made historically. Argenx uses a proprietary technology called SIMPLE Antibody Platform, allowing the company to find answers for complex medical questions. In tandem with its platform technology, Argenx employs several different bioengineering methods.
Traded as ARGX, Argenx is a dual-listed stock, available for trade on the Nasdaq and Euronext exchanges. The company first went public on the Euronext, with a 2014 IPO that gave the company a market valuation of €131.7 million. Argenx was listed on the Nasdaq in 2017, raising almost $100 million with $17 per share.
Argenx often partners with other leading pharmaceutical companies to solve complex medical problems. Some of these partners include LEO Pharma, a skincare provider, Shire, a healthcare company that provides patients with life-saving medical solutions, and Staten Technology, a biotechnology company aiming to remedy cardiovascular ailments.
Diversify and trade. Start now with ARGX stock.
Show More843
Employees
EU
HQ
2008
Founded
Tim van Hauwermeiren, EMBA
CEO
Upcoming Earnings
4
MAY
REPORTS
Argenx Se Q1 2023 earnings report is expected to be released after market open
Consensus
Moderate Buy
Price Target
425.00
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
42
Very Low
Industry
Avg. 47
36
Environment
44
Social
49
Governance
People Also Bought
IPN.PA Ipsen SA -1.47% 
ACKB.BR Ackermans & Van Haaren NV -0.73% 
GBLB.BR Groupe Bruxelles Lambert 0.08% 
UCB.BR UCB SA -0.81% 
EPIA.ST Epiroc AB 0.26%
332.10